What is Zacks Research's Forecast for ResMed Q2 Earnings?

ResMed Inc. (NYSE:RMD - Free Report) - Research analysts at Zacks Research increased their Q2 2025 earnings per share estimates for shares of ResMed in a research report issued to clients and investors on Thursday, December 5th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.25 per share for the quarter, up from their previous forecast of $2.24. The consensus estimate for ResMed's current full-year earnings is $9.34 per share. Zacks Research also issued estimates for ResMed's Q3 2025 earnings at $2.28 EPS, Q4 2025 earnings at $2.35 EPS, FY2025 earnings at $9.08 EPS, Q2 2026 earnings at $2.33 EPS, Q3 2026 earnings at $2.48 EPS, FY2026 earnings at $9.54 EPS, Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.48 EPS.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the previous year, the firm earned $1.64 earnings per share. The business's revenue was up 11.1% on a year-over-year basis.

A number of other research analysts also recently issued reports on RMD. Needham & Company LLC restated a "hold" rating on shares of ResMed in a research report on Friday, October 25th. Wolfe Research restated an "underperform" rating and issued a $180.00 price objective on shares of ResMed in a report on Wednesday, September 18th. StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Bank of America upped their price target on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a research note on Thursday, September 26th. Finally, Robert W. Baird boosted their price objective on shares of ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $225.70.

ResMed Trading Up 1.3 %

Shares of NYSE RMD traded up $3.22 during midday trading on Monday, hitting $244.63. The stock had a trading volume of 583,145 shares, compared to its average volume of 1,025,651. The firm has a market cap of $35.91 billion, a P/E ratio of 32.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.68. ResMed has a fifty-two week low of $162.18 and a fifty-two week high of $260.49. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The company's 50-day simple moving average is $242.31 and its 200 day simple moving average is $226.81.

Institutional Investors Weigh In On ResMed

A number of large investors have recently added to or reduced their stakes in the business. Cetera Advisors LLC acquired a new stake in shares of ResMed during the 1st quarter worth about $257,000. QRG Capital Management Inc. grew its position in shares of ResMed by 4.5% in the second quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider's stock valued at $247,000 after purchasing an additional 56 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of ResMed by 36.1% during the second quarter. SG Americas Securities LLC now owns 26,717 shares of the medical equipment provider's stock worth $5,114,000 after purchasing an additional 7,092 shares during the period. Czech National Bank lifted its holdings in ResMed by 8.2% during the 2nd quarter. Czech National Bank now owns 27,995 shares of the medical equipment provider's stock worth $5,359,000 after purchasing an additional 2,115 shares during the last quarter. Finally, LVW Advisors LLC bought a new stake in ResMed in the 2nd quarter valued at $261,000. Institutional investors own 54.98% of the company's stock.

Insiders Place Their Bets

In related news, CFO Brett Sandercock sold 1,000 shares of the business's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $233.47, for a total transaction of $233,470.00. Following the transaction, the chief financial officer now directly owns 95,812 shares in the company, valued at approximately $22,369,227.64. The trade was a 1.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 14,683 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $231.91, for a total transaction of $3,405,134.53. Following the completion of the sale, the chief executive officer now owns 464,169 shares of the company's stock, valued at approximately $107,645,432.79. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 52,725 shares of company stock valued at $12,516,248 in the last three months. 0.71% of the stock is currently owned by corporate insiders.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a $0.53 dividend. The ex-dividend date is Thursday, November 7th. This represents a $2.12 annualized dividend and a yield of 0.87%. ResMed's payout ratio is currently 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.